STATEMENT OF NEED
Chemotherapy-induced nausea and vomiting (CINV) is one of the most debilitating toxicities associated with cancer treatment. Inadequate control of CINV may not only increase the risk for subsequent emesis but also potentiate inadequate control of nausea and vomiting from other causes in patients with progressive cancer. The introduction of novel antiemetic drug classes, most notably 5-HT3 and NK-1 receptor antagonists, has improved prophylactic strategies, but progress is still needed in our understanding of how to optimally combine antiemetics. Although evidence-based guidelines provide a roadmap for CINV management, treatment must be tailored to individual patients, with a focus on regular monitoring, education, and timely interventions by the entire cancer care team.
Hematology/oncology physicians and other health care professionals involved in the treatment of patients with cancer.
Upon completion of this activity, participants should be able to:
- Assess the mechanisms of action of antiemetic regimens
- Evaluate the risk for nausea and vomiting in cancer patients scheduled to receive chemotherapy
- Differentiate antiemetic strategies for anticipatory, delayed, breakthrough, and refractory nausea and vomiting
Ethan M. Basch, MD (Chairperson)
Director, Cancer Outcomes Research Program
UNC Lineberger Comprehensive Cancer Center
Mark G. Kris, MD
The William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
David S. Ettinger, MD
Alex Grass Professor of Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Lee Schwartzberg, MD
Chief, Division of Hematology Oncology
Washington University School of Medicine
There is no fee to participate in or claim CME credit for this activity.
Please note that Penn State College of Medicine and i3 Health do not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.
Jointly Provided by
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and i3health. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
All individuals in a position to control content have disclosed the following:
Dr. Basch has no relevant disclosures to report
Dr. Kris discloses that he has served as an advisor/consultant for Genentech/Roche, Ariad Pharmaceuticals, and AstraZeneca
Dr. Ettinger discloses that he has served as an advisor/consultant for ARIAD Pharmaceuticals, Boehringer-Ingelheim, BMS, Eli Lilly & Co., EMD Serono, Genentech/Roche, Golden Biotechnology, and Helsinn Therapeutics, Inc
Dr. Schwartzberg discloses that he has served as an advisor/consultant for Tesaro and Eisai. He has received a research grant from Helsinn Therapeutics, Inc
Penn State College of Medicine staff members, i3 Health staff members, and the peer/content reviewer for this activity have no relevant financial relationships to disclose.
UNAPPROVED USE DISCLOSURE
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
This activity is supported by an independent educational grant from Eisai Inc.
The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.
The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, Penn State College of Medicine, i3 Health, or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.